RS.KUSTA Dr. RIVAI ABDULLAH PALEMBANG

DIREKSI YANG BARU

2009-12-15T20:59:00.000-08:00

HOSPITAL OF LEPROSY Dr.RIVAI ABDULLAH PALEMBANG

DIREKSI YANG BARU TMT 02 APRIL 2009 :

1. Direktur : dr. H. HERIYADI MANAN, Sp.OG
2. Wadir Pelayanan dan Rehabilitasi : dr. H. MUHAMMAD ZAQQI MUBARAK, Sp.M.
3. Wadir Adm.Umum dan Keuangan : dr. H. Raden Pamudji, Sp.KK.
4. Ketua Komite Medik : dr. NOPRIYATI, Sp.KK
5. Ka.Bag.Sekretariat : H. MANSYUR ALI, SH.
6. Ka.Bag.Keuangan : drg. HELMY RUSTAM, MM
7. Ka. Bag. Perencanaan dan Rekam Medik : dr.Hj.Iryanti Ismail.M.Kes.
8. Ka.Bidang Pelayanan dan Keperawatan : dr.Hj.Erika Eldayana Ma'az
9. Plt.Ka.Bidang Rehabilitasi Medik : H. MANSYUR ALI, SH

HOSPITAL OF LEPROSY Dr.RIVAI ABDULLAH PALEMBANG

Jumlah Jemaah Haji Wafat 226 Orang

2009-12-14T21:44:00.000-08:00

Jumlah Jemaah Haji Wafat 226 Orang
09 Dec 2009
http://www.depkes.go.id/

Sampai hari ke – 48 (9/12/09) penyelenggaraan ibadah haji, jumlah jamaah haji Indonesia yang wafat (meninggal dunia) sebanyak 226 orang. Dibandingkan dengan periode yang sama tahun 2008 atau musim haji 1429 hijriah sebanyak 376 orang, terjadi penurunan sebesar 39,89 %.

Kejadian luar biasa juga menurun dari 8 kasus pada tahun lalu menjadi 1 kasus pada tahun ini. Sedangkan Balai Pengobatan Haji Indonesia di Mekkah telah merawat 517 pasien rawat inap dan 125.778 rawat jalan.

Menurut indikator yang ditetapkan WHO, menurunnya angka kematian jemaah haji dan menurunnya kejadian luar biasa dalam pergerakan manusia secara massal ( 209.819 orang jamaah haji ) merupakan indikator semakin baiknya pelayanan kesehatan, kata dr. Sjafii Ahmad, MPH, Sekretaris Jenderal Depkes yang juga Ketua Tim Wasdal Yankes Haji 1230 H.

Dari data itu, tercatat 177 orang jamaah haji Indonesia meninggal dunia di Makkah, 23 orang di Madinah, 12 orang di Mina, 9 orang di Jeddah, 3 orang di Arafah dan 2 orang di perjalanan. Dari jumlah itu, 128 orang jamaah yang meninggal adalah pria dan 98 orang wanita. Berdasarkan umur, kurang 40 tahun 2 orang, usia 40-49 tahun 22 orang, usia 50-59 tahun 43 orang dan usia diatas usia 60 tahun 159 orang.

Para jamaah haji yang wafat ini, 75 orang di sejumlah Rumah Sakit Arab Saudi, 59 orang di pemondokan, 50 orang di Balai Pengobatan Haji Indonesia (BPHI), 17 orang di perjalanan, 9 orang di sektor BPHI, 8 orang di mesjid, 7 orang di bandara dan satu orang di pesawat.

Penyebab kematian terbanyak adalah penyakit Infeksi dan parasit, disusul penyakit neoplasma, penyakit darah dan organ pembuluh darah, penyakit endokrin nutrisi dan penyakit gangguan mental dan perilaku.

Berita ini disiarkan oleh Pusat Komunikasi Publik, Sekretariat Jenderal Departemen Kesehatan RI. Untuk informasi lebih lanjut dapat menghubungi melalui nomor telepon/faks: 52907416-9, 52921669, atau alamat e-mail puskom.publik@yahoo.co.id, atau Posko KLB Provinsi Sulawesi Selatan pada nomor telepon/faksimili (0411) 585400 dan email: skd_klb@yahoo.com.

HOSPITAL OF LEPROSY Dr.RIVAI ABDULLAH PALEMBANG

TURUT BERDUKA ATAS MUSIBAH GEMPA SUMATERA BARAT

2009-10-04T20:30:00.000-07:00

HOSPITAL OF LEPROSY Dr.RIVAI ABDULLAH PALEMBANG

DIREKTUR DAN SELURUH STAF RS.KUSTA DR RIVAI ABDULLAH PALEMBANG
" TURUT BERDUKA ATAS MUSIBAH GEMPA SUMATERA BARAT PADA 30 SEPTEMBER 2009 "

Marhaban ya Ramadhan

2009-08-17T21:10:00.000-07:00

HOSPITAL OF LEPROSY Dr.RIVAI ABDULLAH PALEMBANG

edit delete reply

ruvia wrote on Aug 17

"Marhaban ya Ramadhan, mari kita bersihkan hati menyambutnya. Mohon maaf lahir batin. Semoga kita dapat mengerjakan ibadah sekhusuk orang mu'min, InsyaALLAH mendapat door prize Lailatul Qadar. Amin"

Ledakan Bom Beri Sentimen Negatif

2009-07-17T22:25:00.000-07:00

Ledakan Bom Beri Sentimen Negatif

Andri Setyawan

DIREKSI RS.KUSTA DR RIVAI ABDULLAH PALEMBANG

2009-07-12T23:57:00.000-07:00

HOSPITAL OF LEPROSY Dr.RIVAI ABDULLAH PALEMBANG
DIREKSI TERDIRI DARI :

DIREKTUR : dr. H. HERIYADI MANAN, Sp.OG
WAKIL DIREKTUR ADM.UMUM DAN KEUANGAN : Dr. H.R.Pamudji, Sp.KK
WAKIL DIREKTUR PELAYAN DAN REHABILITASI : Dr. H. MZ.MUBARAK, Sp.M
KETUA KOMITE MEDIS : Dr.H. Mustofa Husin Syahab.Sp.OG.

Mengenal Penyakit Kusta Oleh dr. Irene Tantia Utami

2009-07-12T23:53:00.000-07:00

HOSPITAL OF LEPROSY Dr.RIVAI ABDULLAH PALEMBANG

Minggu, 12 Juli 2009 | BP
   
     Mengenal Penyakit Kusta
     Oleh dr. Irene Tantia Utami

     PERNAHKAH Anda atau orang-orang di sekitar mengalami bercak pada kulit
yang mati rasa? Waspadalah, itu bukanlah panu atau kurap, melainkan kusta atau
lepra.

     Penyakit kusta terdengar begitu menakutkan karena cacat tubuh yang
ditimbulkan tampak menyeramkan. Hal ini memberi efek yang sangat besar pada
masyarakat sehingga pasien kusta menderita tidak hanya karena penyakitnya saja,
juga karena dampak sosial yaitu dikucilkan oleh masyarakat. Padahal, dengan
diagnosis dini dan pengobatan tepat, kusta dapat disembuhkan tanpa cacat, serta
rantai penularannya dapat diputuskan.

     Kusta telah ada sejak zaman dahulu, bahkan dikatakan merupakan penyakit
tertua di dunia. Kusta adalah penyakit infeksi kronis, yang disebabkan oleh
kuman mycobacterium leprae. Yang diserang pertama kali adalah saraf tepi,
selanjutnya dapat menyerang kulit, selaput lendir mulut, saluran nafas bagian
atas, dan organ tubuh lain kecuali susunan saraf pusat.

     Penularan dan Gejala

     Penularan penyakit kusta belum diketahui dengan pasti, tetapi sebagian
besar para ahli mengatakan bahwa penularannya melalui saluran pernafasan dan
kontak langsung antar-kulit yang lama dan erat, namun gejala klinis dan tingkat
keparahannya berbeda antar-individu tergantung pada jumlah kuman, keganasannya,
dan daya tahan tubuh penderita.

     Pada kulit, gejala yang menonjol adalah berupa bercak kemerahan,
kehitaman, atau bercak keputihan, sehingga sering dianggap panu atau kurap.
Namun pada kusta, bercak tersebut disertai dengan hilangnya sensasi rasa atau
mati rasa, yang dapat diuji menggunakan jarum untuk rasa nyeri, kapas untuk
mengetahui rasa raba, dan tabung reaksi berisi air panas dan dingin untuk
menguji rasa suhu.

     Gejala pada saraf tepi dapat diperiksa melalui beberapa titik saraf,
antara lain saraf pada wajah, leher, tangan dan kaki. Dapat dilihat dari
pembesaran atau penebalan saraf, kekenyalannya, dan apakah terdapat rasa nyeri.
Gangguan saraf yang terkena dapat berupa gangguan fungsi sensoris, yaitu mati
rasa, fungsi motoris, yaitu kelemahan atau kelumpuhan anggota gerak tubuh, dan
gangguan fungsi otonom berupa kulit kering, retak, bengkak, dan pertumbuhan
rambut yang terganggu. Pada tahap lanjut dapat terjadi penghancuran saraf,
dimana kelumpuhan akan menetap, dapat terjadi infeksi yang progresif dengan
kerusakan tulang hingga terjadi mutilasi.

     Kuman penyakit kusta juga dapat menyerang organ lain, di antaranya mata,
hidung, lidah, pita suara, testis, kelenjar limfe, dan ginjal. Pada mata dapat
terjadi peradangan pada iris, gangguan penglihatan, sampai kebutaan. Pada
hidung dapat terjadi perdarahan dari selaput lendir hidung, atau biasa disebut
mimisan, dan kelainan anatomis berupa hidung pelana. Dapat juga terjadi luka
pada lidah seperti sariawan dan benjolan pada lidah, suara parau, infeksi
kelenjar limfe, dan infeksi ginjal.

     Untuk menegakkan diagnosis penyakit kusta, selain terdapat satu di antara
gejala klinis pada kulit dan saraf tepi, juga harus dilakukan pemeriksaan
penunjang untuk menentukan ada tidaknya kuman mycobacterium leprae, yaitu
berupa pemeriksaan bakterioskopik. Sediaan dapat diambil dari kerokan atau
hapusan pada kulit yang paling aktif, di antaranya cuping telinga, lengan,
punggung, bokong, dan paha, dimana minimal dilakukan pada tiga tempat, yaitu
cuping telinga kanan, kiri, dan bercak yang paling aktif, kemudian setelah
dilakukan pengecatan dengan bahan tertentu, sediaan tersebut diperiksa di bawah
mikroskop. Dari hasil pemeriksaan dapat dibedakan mana kuman yang solid atau
masih aktif dan mana yang sudah tidak aktif.

     Untuk kepentingan pengobatan, WHO membagi penyakit kusta menjdi dua tipe,
yaitu tipe Pausibasiler (PB), dan tipe Multibasiler (MB). Pada kusta tipe PB
terdapat 1-5 buah bercak pada kulit dengan distribusi yang tidak simetris,
hilangnya sensasi rasa yang jelas dan hanya mengenai satu cabang saraf, namun
memberi hasil pemeriksaan bakterioskopik yang negatif. Sedangkan pada kusta
tipe MB ditandai dengan adanya bercak atau kelainan pada kulit lebih dari lima
buah, dengan distribusi yang lebih simetris, hilangnya sensasi rasa kurang
jelas namun mengenai banyak cabang saraf, serta ditemukan hasil yang positif
pada pemeriksaan bakterioskopik.

     Upaya Penanganan

     Pengobatan penyakit kusta di Indonesia ditanggung oleh pemerintah, jadi
penderita yang telah didiagnosa menderita kusta tidak perlu mengeluarkan biaya
untuk memperoleh pengobatan di instansi yang telah ditunjuk oleh pemerintah.
Tersedia paket pengobatan yang dikenal dengan nama MDT (Multi Drug Treatment)
yang terdiri dari tiga macam obat, yaitu DDS, klofazimin, dan rifampisin.
Pengobatan disesuaikan dengan klasifikasi kusta, jika tergolong PB penderita
mendapatkan 6 paket MDT-PB yang harus dihabiskan dalam jangka waktu 6-9 bulan.
Sedangkan bagi penderita yang tergolong MB akan mendapatkan 12 paket MDT-MB
yang harus habis dalam waktu 12-18 bulan.

     Dengan pengobatan yang tepat dan adekuat, diharapkan penderita dapat
terhindari dari risiko terjadinya kecacatan, dan untuk penderita yang sudah
mengalami kecacatan dapat dicegah agar cacat yang terjadi tidak menjadi lebih
berat dan tidak kambuh lagi. Beberapa upaya untuk mencegah terjadinya cacat
sekunder antara lain perawatan diri sendiri untuk mencegah luka, perawatan luka
yang benar, fisioterapi pada otot yang mengalami kelumpuhan, tindakan
pembedahan untuk mengurangi perluasan infeksi dan rekontruksi untuk otot yang
lumpuh, dan perawatan pada mata, tangan, atau kaki yang mengalami mati rasa
atau kelumpuhan.

     Sangat diperlukan kesadaran dari tiap lapisan masyarakat untuk dapat ikut
serta dalam menanggulangi kusta bukan dengan cara menjauhi mereka, melainkan
mengarahkan mereka untuk mendapatkan pengobatan. Untuk penderita kusta agar
tidak rendah diri, segeralah memeriksakan diri ke tempat pelayanan kesehatan
terdekat, jangan menunggu hingga terjadi kecacatan. Ingatlah, penyakit kusta
dapat disembuhkan dengan penanganan yang tepat. (*)

HOSPITAL OF LEPROSY Dr.RIVAI ABDULLAH PALEMBANG

2009-03-04T23:09:00.001-08:00

HOSPITAL OF LEPROSY Dr.RIVAI ABDULLAH PALEMBANG

RSK.Dr.RIVAI ABDULLAH PALEMBANG ON THE PICTURE

2009-03-04T22:37:00.000-08:00

HOSPITAL OF LEPROSY Dr.RIVAI ABDULLAH PALEMBANG

Pamong-Pamong TAMANSISWA SEI.GERONG

2009-03-04T21:24:00.000-08:00

GAMBAR / FOTO PAMONG SD TAMANSISWA SUNGAI GERONG

DIREKSI YANG BARU

2009-03-04T20:27:00.000-08:00

HOSPITAL OF LEPROSY Dr.RIVAI ABDULLAH PALEMBANG
DIREKSI YANG BARU :

DIREKTUR : Dr. H. Heriyadi Manan, Sp.OG
WADIR ADM.UMUM & KEUANGAN : Dr. H.Raden Pamudji, Sp.KK
WADIR PELAYANAN & REHABILITASI : Dr. H. Muhammad Zaqqi Mubaraq, Sp.M
Ketua Komite Medis : Dr. H. Mustofa Husin Syahab, Sp.OG
Ka.Bag.Sekretariat : H. Mansyur Ali, SH
Ka.Bag.Keuangan :
Ka.Bag. Perencanaan dan Rekam Medik : Dr. Hj. Iryanti Ismail, M.Kes.
Ka.Bid. Pelayanan dan Keperawatan : Dr. Hj. Eryka Eldayana Maaz
Ka. Bid. Rehabilitasi :

2009-01-28T01:29:00.000-08:00

HOSPITAL OF LEPROSY Dr.RIVAI ABDULLAH PALEMBANG

OPTIMALISASI PELAYANAN PROFESIONAL
DALAM UPAYA MEWUJUDKAN RSK Dr.RIVAI ABDULAH
SEBAGAI KEBANGGAAN NASIONAL BERKONSEP
AGRO SOCIAL MEDICAL TOURISM HOSPITAL
TAHUN 2008

SEJARAH RSK dr.RIVAI ABDULAH PALEMB
DIDIRIKAN 1914 à TEMPAT PENAMPUNGAN (PENGASINGAN)
NAKODA BELANDA ABK PENYAKIT KUSTA à “KEMBANG RUMPUNG”
DAERAH KERTAPATI PINDAH à MARIANA 120 Ha à 27,5 Ha
MISI à“YAYASAN BALA KESELAMATAN”
SK MENKES RI à 1-4-1961 DISERAHKAN KE PEMERINTAH RI
NO.95048/9-12-1960 DEPKES RI à DIRJEN YANMED
SK MENKES RI à RS RUJUKAN KUSTA REGIONAL
NO.185/26-2-1993 WIL.INDONESIA BAG.BARAT
NAMA à RS.KUSTA SUNGAI KUNDUR (ESELON II.B)
LOKASI à DI PALEMBANG SUMATERA SELATAN
SP DIRJEN YANMED à KUSTA + PELAYANAN UMUM
TGL. 31-10-1995
SK MENKES RI NO.630à P’RUBAH NAMA
TGL.10 AGUS 2006 RS Kusta Dr.RIVAI ABDULAH PALEMBANG
ANG

LEPROSY

2008-04-10T20:19:00.000-07:00

HOSPITAL OF LEPROSY Dr.RIVAI ABDULLAH PALEMBANG
Leprosy
www.searo.who.int/en/Section10/Section20/Section2293.htm
Fact Sheet
Cause
Leprosy is a chronic disease caused by a bacillus, Mycobacterium leprae (M. laprae).
M. leprae multiplies very slowly and the incubation period of the disease is considered to be about five years.

TRANSMISSION
Leprosy is transmitted by air through droplets from the nose and mouth, during close and frequent contacts with untreated cases.
Leprosy is one of the least infectious diseases, because:

Over 99% of the population has adequate natural immunity;
Over 85% of the clinical cases are non-infectious, and
An infectious case is rendered non-infectious within one week, most often after the very first dose of treatment.

SYMPTOMS
Leprosy mainly affects the skin and peripheral nerves.
If left untreated, it can lead to progressive and permanent damage of nerves, leading to loss of sensation and sweating in the extremities and paralysis of muscles in the hands, feet and face.
The disease is classified as paucibacillary (PB) or multibacillary (MB), depending on the bacillary load.
PB leprosy is a milder disease characterized by few (up to five) skin lesions (pale or reddish), whereas MB is associated with multiple (more than five) skin lesions, nodules, plaques, thickened dermis or skin infiltration.

HISTORY OF THE DISEASE
The first known written mention of leprosy is dated 600 BC.
Leprosy was recognized in the ancient civilizations of China, Egypt and India.
All countries of the South-East Asia Region were known to be endemic for leprosy.
Throughout history, the afflicted have often been ostracized by their communities and families. This situation has changed since leprosy is now completely curable and there is greater awareness about the disease.

HISTORY OF TREATMENT
The first breakthrough occurred in the 1940s with the development of the drug dapsone, which cured the disease. But the duration of the treatment of leprosy was many years, even a lifetime, making it difficult for patients to be regular in their treatment.
In the 1960s, M. leprae started to develop resistance to dapsone, the world’s only known anti-leprosy drug at that time.

TREATMENT TODAY
In 1981, a World Health Organization (WHO) Study Group recommended multi-drug therapy (MDT), a combination of three drugs.
MDT effectively kills the pathogen and cures the patient.
Treatment provided in the early stages averts disability.
With minimal training, leprosy can be easily diagnosed by clinical signs alone.

WHAT IS MDT
MDT comprises of three drugs, dapsone, rifampicin and clofazimine. Rifampicin and clofazimine were discovered in the early 1960s.
MDT is safe, effective and easily administered under field conditions.
MDT is available in convenient monthly calendar blister packs.
Since 1995, WHO has been providing free MDT for all patients in the world, initially through the drug fund provided by the Nippon Foundation and since 2000, through the MDT donation provided by Novartis and the Novartis Foundation for Sustainable Development.
Novartis has pledged free supply of MDT till 2010.

HIGH EFFECTIVENESS OF MULTIDRUG THERAPY
Transmission of leprosy is interrupted after the very first dose of MDT. In other words, patients are no longer infectious to others after being administered the first dose of the treatment regimen.
PB patients treated with MDT are cured within six months.
MB patients treated with MDT are cured within 12 months.
There are virtually no relapses, i.e. no recurrences of the disease after treatment is completed.
No resistance of the bacillus to MDT has been detected.
WHO estimates that early detection and treatment with MDT has prevented about four million people from becoming disabled.
MDT is very cost-effective as a health intervention, considering the economic and social losses averted.

THE ELIMINATION OF LEPROSY AS A PUBLIC HEALTH PROBLEM
In 1991 World Health Assembly passed a resolution to eliminate leprosy as a public health problem by the year 2000. Elimination of leprosy as a public health problem is defined as a prevalence rate of less than one case per 10,000 population.
Globally, the leprosy elimination goal was achieved in 2000.
The global disease burden reduced from 5.2 million in 1985 to 805,000 in 1995 to 753,000 at the end of 1999 to about 219,826 cases at the end of 2005.
The South-East Asia Region, including India, achieved the elimination goal in December 2005.
The Regional prevalence rate steadily declined from 4.6/10,000 population in 1996 to 0.82/10,000 population as of July 2006.
The Regional new case detection also declined from a peak of 47.8/100,000 in 1998 to 11.9/100,000 as of March 2006.
Between 1985 and 2005, more than 15 million leprosy cases were cured globally. Of these, about 12.8 million were from the SEA Region, of which India accounted for about 11.8 million.
The SEA Region has made substantial contribution to the achievement of leprosy elimination globally.

CURRENT LEPROSY SITUATION
At the beginning of 2006, about 219,826 cases were under MDT globally and the prevalence rate was about 0.2 per 10,000 population.
Globally, 296,499 new cases of leprosy were detected during 2005.
The top 10 countries in new case detection in 2005 are India, Brazil, Indonesia, DR Congo, Bangladesh, Nepal, Mozambique, Nigeria, Ethiopia and Tanzania. Together, they constitute about 96% of the 2005 global new case detection.
The SEA Region contributed to about 69% of the 2005 global new case detection.
Six countries (small countries with <1 million population excluded), Brazil, DR Congo, Madagascar, Mozambique, Nepal and Tanzania are yet to achieve the elimination goal.
In the SEA Region, two countries, Nepal and Timor-Leste (population of Timor-Leste is less than 1 million) are yet to achieve elimination.
As of December 2005, the PR in Nepal was 1.81/10,000 and Timor-Leste 1.89/10,000 population. These countries are expected to achieve elimination in 2006 or 2007.

REMAINING CHALLENGES
Achieving elimination in the remaining countries and sustaining elimination in the countries that have achieved the goal at the national level.
Sustaining political commitment and ensuring adequate resources in order to sustain elimination at national level, and progress towards further reducing the burden of leprosy.
Strengthening integration of leprosy services into the general health system through capacity building and skill development, in order to ensure and sustain quality leprosy services, including diagnosis and treatment and prevention/care of disabilities.
Ensuring a wider coverage of leprosy services, especially in currently under-served population groups such as remote rural areas, urban slums, migrant labour.
Increasing and sustaining community awareness through sustained advocacy and IEC activities to promote voluntary case detection and decrease the stigma.
Minimizing/preventing operational factors, such as:

Setting case detection targets and basing performance appraisal on target achievement
Over-diagnosis and re-registration of cases due to:

Non-adherence to WHO-recommended case definitions
Active search and surveys repeatedly targeting the same population groups
Repeated leprosy elimination campaigns in the same areas
Lack of “Quality” and “Accuracy” of diagnosis

Multiple registration
Wrong classification - PB cases recorded as MB (more frequent than vice-versa)
Delayed treatment completion due to:

Irregularity
Drug shortage at peripheral level

Delayed release from treatment
Over-treatment
Non-existent cases
Job insecurity among vertical staff leading to large number of suspect/doubtful cases being recorded as leprosy cases

Preventing discrimination and displacement of leprosy affected and ensuring community based rehabilitation and integration of cured/disabled leprosy persons into the community.
Streamlining the MDT supply and stock management at all levels, considering the low endemic situation.
Strengthening existing partnerships and identifying new partners to support leprosy activities.

THE STRATEGY FOR LEPROSY ELIMINATION
Sustain leprosy services and activities in all endemic countries.
Use annual new case detection and cure rates as the main indicator to monitor progress.
Ensure high-quality diagnosis, case management, recording and reporting in all endemic countries.
Strengthen routine and referral services.
Discontinue the campaign approach, since they are not cost-effective any more and lead to over-detection.
Develop tools and procedures that are home/community-based, integrated and locally appropriate for the prevention of disabilities/impairments and for the provision of rehabilitation services.
Promote operational research in order to improve implementation of a sustainable strategy.
Encourage supportive working arrangements with partners at all levels.

DIREKSI YANG BARU

2008-04-09T21:47:00.000-07:00

DIREKSI YANG BARU TMT 01 FEBRUARI 2008 :

1. Direktur : dr. H. Bayu Wahyudi, MPH.M, Sp.OG
2. Wadir Pelayanan dan Rehabilitasi : dr. H. Raden Pamudji, Sp.KK.
3. Wadir Adm.Umum dan keuangan : Dra. Hj. Kartini, MARS.
4. Ketua Komite Medik : dr. H. Mustofa Husin Syahab, Sp.OG

LEPROSY

2008-04-09T20:29:00.000-07:00

LEPROSY

www.searo.who.int/en/Section10/Section20/Section2293.htm

Fact Sheet

Cause

Leprosy is a chronic disease caused by a bacillus, Mycobacterium leprae (M. laprae).

M. leprae multiplies very slowly and the incubation period of the disease is considered to be about five years.

TRANSMISSION

Leprosy is transmitted by air through droplets from the nose and mouth, during close and frequent contacts with untreated cases.

Leprosy is one of the least infectious diseases, because:

Over 99% of the population has adequate natural immunity;

Over 85% of the clinical cases are non-infectious, and

An infectious case is rendered non-infectious within one week, most often after the very first dose of treatment.

SYMPTOMS

Leprosy mainly affects the skin and peripheral nerves.

If left untreated, it can lead to progressive and permanent damage of nerves, leading to loss of sensation and sweating in the extremities and paralysis of muscles in the hands, feet and face.

The disease is classified as paucibacillary (PB) or multibacillary (MB), depending on the bacillary load.

PB leprosy is a milder disease characterized by few (up to five) skin lesions (pale or reddish), whereas MB is associated with multiple (more than five) skin lesions, nodules, plaques, thickened dermis or skin infiltration.

HISTORY OF THE DISEASE

The first known written mention of leprosy is dated 600 BC.

Leprosy was recognized in the ancient civilizations of China, Egypt and India.

All countries of the South-East Asia Region were known to be endemic for leprosy.

Throughout history, the afflicted have often been ostracized by their communities and families. This situation has changed since leprosy is now completely curable and there is greater awareness about the disease.

HISTORY OF TREATMENT

The first breakthrough occurred in the 1940s with the development of the drug dapsone, which cured the disease. But the duration of the treatment of leprosy was many years, even a lifetime, making it difficult for patients to be regular in their treatment.

In the 1960s, M. leprae started to develop resistance to dapsone, the world’s only known anti-leprosy drug at that time.

TREATMENT TODAY

In 1981, a World Health Organization (WHO) Study Group recommended multi-drug therapy (MDT), a combination of three drugs.

MDT effectively kills the pathogen and cures the patient.

Treatment provided in the early stages averts disability.

With minimal training, leprosy can be easily diagnosed by clinical signs alone.

WHAT IS MDT

MDT comprises of three drugs, dapsone, rifampicin and clofazimine. Rifampicin and clofazimine were discovered in the early 1960s.

MDT is safe, effective and easily administered under field conditions.

MDT is available in convenient monthly calendar blister packs.

Since 1995, WHO has been providing free MDT for all patients in the world, initially through the drug fund provided by the Nippon Foundation and since 2000, through the MDT donation provided by Novartis and the Novartis Foundation for Sustainable Development.

Novartis has pledged free supply of MDT till 2010.

HIGH EFFECTIVENESS OF MULTIDRUG THERAPY

Transmission of leprosy is interrupted after the very first dose of MDT. In other words, patients are no longer infectious to others after being administered the first dose of the treatment regimen.

PB patients treated with MDT are cured within six months.

MB patients treated with MDT are cured within 12 months.

There are virtually no relapses, i.e. no recurrences of the disease after treatment is completed.

No resistance of the bacillus to MDT has been detected.

WHO estimates that early detection and treatment with MDT has prevented about four million people from becoming disabled.

MDT is very cost-effective as a health intervention, considering the economic and social losses averted.

THE ELIMINATION OF LEPROSY AS A PUBLIC HEALTH PROBLEM

In 1991 World Health Assembly passed a resolution to eliminate leprosy as a public health problem by the year 2000. Elimination of leprosy as a public health problem is defined as a prevalence rate of less than one case per 10,000 population.

Globally, the leprosy elimination goal was achieved in 2000.

The global disease burden reduced from 5.2 million in 1985 to 805,000 in 1995 to 753,000 at the end of 1999 to about 219,826 cases at the end of 2005.

The South-East Asia Region, including India, achieved the elimination goal in December 2005.

The Regional prevalence rate steadily declined from 4.6/10,000 population in 1996 to 0.82/10,000 population as of July 2006.

The Regional new case detection also declined from a peak of 47.8/100,000 in 1998 to 11.9/100,000 as of March 2006.

Between 1985 and 2005, more than 15 million leprosy cases were cured globally. Of these, about 12.8 million were from the SEA Region, of which India accounted for about 11.8 million.

The SEA Region has made substantial contribution to the achievement of leprosy elimination globally.

CURRENT LEPROSY SITUATION

At the beginning of 2006, about 219,826 cases were under MDT globally and the prevalence rate was about 0.2 per 10,000 population.

Globally, 296,499 new cases of leprosy were detected during 2005.

The top 10 countries in new case detection in 2005 are India, Brazil, Indonesia, DR Congo, Bangladesh, Nepal, Mozambique, Nigeria, Ethiopia and Tanzania. Together, they constitute about 96% of the 2005 global new case detection.

The SEA Region contributed to about 69% of the 2005 global new case detection.

Six countries (small countries with <1 st="on">Brazil, DR Congo, Madagascar, Mozambique, Nepal and Tanzania are yet to achieve the elimination goal.

In the SEA Region, two countries, Nepal and Timor-Leste (population of Timor-Leste is less than 1 million) are yet to achieve elimination.

As of December 2005, the PR in Nepal was 1.81/10,000 and Timor-Leste 1.89/10,000 population. These countries are expected to achieve elimination in 2006 or 2007.

REMAINING CHALLENGES

Achieving elimination in the remaining countries and sustaining elimination in the countries that have achieved the goal at the national level.

Sustaining political commitment and ensuring adequate resources in order to sustain elimination at national level, and progress towards further reducing the burden of leprosy.

Strengthening integration of leprosy services into the general health system through capacity building and skill development, in order to ensure and sustain quality leprosy services, including diagnosis and treatment and prevention/care of disabilities.

Ensuring a wider coverage of leprosy services, especially in currently under-served population groups such as remote rural areas, urban slums, migrant labour.

Increasing and sustaining community awareness through sustained advocacy and IEC activities to promote voluntary case detection and decrease the stigma.

Minimizing/preventing operational factors, such as:

Setting case detection targets and basing performance appraisal on target achievement

Over-diagnosis and re-registration of cases due to:

Non-adherence to WHO-recommended case definitions

Active search and surveys repeatedly targeting the same population groups

Repeated leprosy elimination campaigns in the same areas

Lack of “Quality” and “Accuracy” of diagnosis

Multiple registration

Wrong classification - PB cases recorded as MB (more frequent than vice-versa)

Delayed treatment completion due to:

Irregularity

Drug shortage at peripheral level

Delayed release from treatment

Over-treatment

Non-existent cases

Job insecurity among vertical staff leading to large number of suspect/doubtful cases being recorded as leprosy cases

Preventing discrimination and displacement of leprosy affected and ensuring community based rehabilitation and integration of cured/disabled leprosy persons into the community.

Streamlining the MDT supply and stock management at all levels, considering the low endemic situation.

Strengthening existing partnerships and identifying new partners to support leprosy activities.

THE STRATEGY FOR LEPROSY ELIMINATION

Sustain leprosy services and activities in all endemic countries.

Use annual new case detection and cure rates as the main indicator to monitor progress.

Ensure high-quality diagnosis, case management, recording and reporting in all endemic countries.

Strengthen routine and referral services.

Discontinue the campaign approach, since they are not cost-effective any more and lead to over-detection.

Develop tools and procedures that are home/community-based, integrated and locally appropriate for the prevention of disabilities/impairments and for the provision of rehabilitation services.

Promote operational research in order to improve implementation of a sustainable strategy.

Encourage supportive working arrangements with partners at all levels.

www.searo.who.int/en/Section10/Section20/Section2293.htm

DIREKSI

2008-01-06T22:23:00.000-08:00

DIREKTUR : Dr. H. Bayu Wahyudi, MPH.M, Sp.OG
WADIR ADM.UMUM & KEUANGAN : Drs. Idham Tergun, MM
WADIR PELAYANAN & REHABILITASI : Dr. H. Raden Pamudji, Sp.KK
Ketua Komite Medis : Dr. H. Mustofa Husin Syahab, Sp.OG

ALAMAT

2008-01-06T22:09:00.001-08:00

Jl. Sungai Kundur Kelurahan Mariana
Kecamatan Banyuasin I - Kabupaten Banyuasin
Provinsi Sumatera Selatan
Indonesia Kode Pos Mariana 30763
Kotak Pos 1364 Palembang 30000
Telp.0711-537201 - Fax : 0711-537204
Alamat Email : rsdr_rivaiadullah@yahoo.co.id
atau : rsrivaiabdullah@gmail.com

Hubungi Bagian Informasi
RUMAH SAKIT KUSTA Dr. RIVAI ABDULLAH PALEMBANG
Telp.(0711)537201 Ext. 220

ALAMAT

2008-01-06T22:09:00.000-08:00

FASILITAS UMUM

2008-01-06T22:06:00.000-08:00

1. Sarana Sport Centre
2. Gedung Serba Guna
3. Penginapan/Guest House
4. Kolam pemancingan ikan
5. Hospital garden

KEPUASAN ANDA ADALAH TUJUAN KAMI

PELAYANAN POLIKLINIK

2008-01-06T22:04:00.002-08:00

Jam buka poliklinik adalah sbb :
1. Senin s.d Kamis : 08.00 s.d 13.00 WIB
2. Jum'at : 08.00 s.d 11.00 WIB
3. Sabtu : 08.00 s.d 12.00 WIB

PELAYANAN POLIKLINIK

2008-01-06T22:04:00.001-08:00

FASILITAS PELAYANAN

2008-01-06T21:30:00.000-08:00

I. IRD (IGD) 24 JAM
Instalasi rawat Darurat yang siap melayani 24 jam, ditunjang oleh sarana yang baik dan
dan tenaga yang profesional.

II.UNIT LAYANAN
*)Pelayanan pasien kusta terdiri dari :
- Rawat Jalan
- Rawat Inap
- Kamar Operasi/Bedah rekonstruksi
- Fisioterapi
- Okupasi terapi
- Protesa & Orthosa
- Laboratorium
- Rehabilitasi Karya
- Rehabiltasi Medis
- Rehabilitasi Sosial
- Farmasi
- Ambulance
- Radiologi
- Psikologi
- Gizi

*)Pelayanan Pasien Umum terdiri dari :
1. Rawat Jalan
a. Poliklinik Penyakit Dalam
b. Poliklinik Kebidanan, BKIA
c. Poliklinik Mata
d. Poliklinik Gigi
e. Poliklinik Anak
f. Poliklinik Bedah
g. Poliklinik THT
h. Poliklinik Kulit, Kelamin dan Kecantikan
i. Psikologi
j. Fisioterapi
k. Okupasi terapi
l. Protesa & Orthosa
m. Laboratorium 24 jam
n. Radiologi 24 jam
o. Farmasi 24 jam
p. Gizi

2. Rawat Inap
a. Ruang rawat inap umum terpisah dengan ruang rawat inap kusta.
b. Kapasitas tempat tidur 50 TT terdiri dari :
- Kelas I, sebanyak 5 tempat tidur
- Kelas II, sebanyak 10 tempat tidur
- Kelas III, sebanyak 35 tempat tidur

3. Instalasi Bedah
Pelayanan operasi/bedah meliputi bedah rekonstruksi, bedah umum, Sectio Caesarian (SC),
perasi mata, bedah kulit dan tindakan operasi kecil lainnya.

III. SARANA & PENUNJANG MEDIK
Untuk menunjang pelayanan, kami menyediakan :
1. USG Kebidanan
2. Ultrasound with imazing system
3. USG Fisioterapi
4. Diathermy
5. E K G
6. Laboratorium
7. Radiologi
8. Kamar Operasi
9. Konsultasi Gizi
10. Apotik 24 jam
11. Mobil Ambulance 118
12. Mobil Jenazah
13. Kolam Renang Rehabilitasi medik
14 Dermaga dan Poliklinik Terapung

SUMBER DAYA MANUSIA / KETENAGAAN

2008-01-06T21:16:00.000-08:00

1. Dokter Spesialis Kulit & Kecantikan : 2 orang
2. Dokter Spsialis Obgin (Kebidanan) : 3 orang
3. Dokter Spesialis Mata : 2 orang
4. Dokter Spesialis Anaesthesi : 1 orang
5. Dokter Spesialis Penyakit Dalam : 2 orang
6. Dokter Spesialis Anak : 2 orang
7. Dokter Spesialis Gigi Anak : 1 orang
8. Dokter Gigi : 1 orang
9. Dokter Umum : 15 orang
10. Sarjana Farmasi/Apoteker : 3 orang
11. Psikolog : 1 orang
12. Paramedis Perawatan : 112 orang
13. Paramedis Non Perawatan : 46 orang
14. Non medis non Paramedis : 125 orang

VISI DAN MISI

2008-01-06T21:08:00.000-08:00

VISI :
- Terwujudnya Pelayanan Kesehatan Masyarakat yang optimal dengan Unggulan Kusta dan Pelayanan Spesifik Spesialistik.

MISI :
1. Meningkatkan disiplin karyawan
2. Meningkatkan dan memenuhi kualitas dan kuantitas sumber daya manusia
3. Memenuhi dan membedayakan secara optimal sarana dan prasarana sesuai kebutuhan
4. Membuat kebijakan yang tepat sesuai Visi Rumah Sakit
5. Membina kerjasama lintas sektoral
6. Meningkatkan pembinaan di wilayah binaan
7. Menjadikan Rumah Sakit sebagai tujuan wisata medis dan wisata sosial
8. Menjadikan Rumah Sakit sebagai pusat riset dan pelayan rujukan penyakit tropis,
rawa dan perairan

MOTTO

2008-01-06T21:05:00.000-08:00

"MEMBERIKAN PELAYANAN YANG OPTIMAL AGAR ANDA DAPAT BERKARYA DAN LEBIH PRODUKTIF"

RS.KUSTA Dr. RIVAI ABDULLAH PALEMBANG

DIREKSI YANG BARU

Jumlah Jemaah Haji Wafat 226 Orang

TURUT BERDUKA ATAS MUSIBAH GEMPA SUMATERA BARAT

Marhaban ya Ramadhan

Ledakan Bom Beri Sentimen Negatif

Ledakan Bom Beri Sentimen Negatif

Artikel Terkait

17/07/2009 16:33

DIREKSI RS.KUSTA DR RIVAI ABDULLAH PALEMBANG

Mengenal Penyakit Kusta Oleh dr. Irene Tantia Utami

HOSPITAL OF LEPROSY Dr.RIVAI ABDULLAH PALEMBANG

RSK.Dr.RIVAI ABDULLAH PALEMBANG ON THE PICTURE

Pamong-Pamong TAMANSISWA SEI.GERONG

DIREKSI YANG BARU

LEPROSY

DIREKSI YANG BARU

LEPROSY

DIREKSI

ALAMAT

ALAMAT

FASILITAS UMUM

PELAYANAN POLIKLINIK

PELAYANAN POLIKLINIK

FASILITAS PELAYANAN

SUMBER DAYA MANUSIA / KETENAGAAN

VISI DAN MISI

MOTTO